Form 4: Terns Pharmaceuticals CFO Andrew Gengos Boosts Stake with Recent Share Purchases

Terns Pharmaceuticals, Inc.'s Chief Financial Officer, Andrew Gengos, has acquired 15,000 shares of common stock through open market purchases in mid-June 2025, signaling strong insider confidence.

Summary

• Andrew Gengos, Chief Financial Officer of Terns Pharmaceuticals, Inc. (TERN), reported multiple open market purchases of the company's common stock.
• On June 13, 2025, Mr. Gengos purchased 5,000 shares at a price of $3.75 per share.
• Also on June 13, 2025, he acquired an additional 5,000 shares at $3.72 per share.
• On June 16, 2025, Mr. Gengos purchased another 5,000 shares at $3.9465 per share.
• Following these transactions, Andrew Gengos directly beneficially owns a total of 15,000 shares of Terns Pharmaceuticals, Inc. common stock.

Sentiment

Score: 8

Explanation: The Chief Financial Officer's open market purchases indicate strong insider confidence in the company's future prospects, which is a positive signal for investors.

Positives

• The Chief Financial Officer, Andrew Gengos, made open market purchases of 15,000 shares of Terns Pharmaceuticals common stock, signaling strong insider confidence in the company's valuation and future prospects.
• The purchases were made at varying price points between $3.72 and $3.9465, indicating a belief in the stock's value at these levels.

Negatives

• No negative information is disclosed in this Form 4 filing, as it solely reports insider stock transactions.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing reports specific insider transactions and does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

As a pharmaceutical company, Terns Pharmaceuticals operates in a sector characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Insider buying, such as reported here, can be interpreted by investors as a positive signal regarding the company's pipeline progress or market positioning within this competitive industry.

Comparison to Industry Standards

• This Form 4 filing reports specific insider transactions and does not provide financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders may perceive the CFO's share purchases as a vote of confidence in the company's future, potentially leading to increased investor interest.
• Employees might view the insider buying as a positive sign regarding the company's stability and prospects.

Key Dates

Recommendation

Keywords

Terns Pharmaceuticals, TERN, Andrew Gengos, CFO, Insider Trading, Share Purchase, Form 4, Beneficial Ownership, Biotechnology, Pharmaceuticals